Expanding Business Scale and Enhancing Earnings Power
First written in FY2017-Q1. 17 of 38 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2027-H1.
The whole theme swung hardest in 2020: 14 of 68 companies on the "Worse" side.
32 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「Accordingly, while promoting business expansion and operational efficiency, the company is working to strengthen its earnings base. As part of these efforts, during the interim consolidated accounting period it acquired a pharmaceutical wholesaling business in Saga Prefecture. Going forward, it will continue to expand its business base by leveraging M&A and other means. As a result, the group's results for the interim consolidated accounting period were revenue of ¥28,255 million, up 4.9% year on year, operating income of ¥821 million, up 10.4%, ordinary income of ¥1,135 million, up 29.0%, and interim net income attributable to owners of the parent of ¥850 million, up 27.5%.」
While expanding its business scale, improving operational efficiency and strengthening its earnings base, the company acquired a pharmaceutical wholesaling business in Saga Prefecture. Interim revenue rose 4.9%, operating income 10.4% and ordinary income 29.0%, among other increases. - FY2026AdvancedAnnual report
「In April 2025, we formulated a medium-term management plan targeting net sales of ¥60 billion and operating profit of ¥2.5 billion for the fiscal year ending February 2028. We will rebuild the organization and operating structure to enable long-term, sustainable growth and advance each business.」
Under the medium-term management plan targeting net sales of ¥60 billion and operating profit of ¥2.5 billion for the fiscal year ending February 2028, the current fiscal year produced net sales of ¥54.98 billion and operating profit of ¥1.79 billion, while the company continued to expand its business scale through M&A and increase sales and profits. - FY2026-H1AdvancedAnnual report
「Taking this opportunity, we formulated a medium-term management plan and, to accelerate further growth over the next 3 years, positioned the current fiscal year as the first year of “Re-Start,” while working to ensure the safety of patients and users and expand our business activities.」
Taking the 40th anniversary of the company's establishment in April 2025 as an opportunity, it formulated a medium-term management plan and is expanding its business activities as the first year of a 3-year drive to accelerate growth. - FY2025RaisedAnnual report
「In April 2025, we formulated a medium-term management plan targeting net sales of ¥60 billion and operating profit of ¥2.5 billion for the fiscal year ending February 2028. We will rebuild the organization and operating structure to enable long-term, sustainable growth and advance each business.」
Replacing the previous plan targeting net sales of ¥35 billion and ordinary profit of ¥1.5 billion for the fiscal year ending February 2024, the company set new numerical targets of net sales of ¥60 billion and operating profit of ¥2.5 billion for the fiscal year ending February 2028. - FY2025-H1AchievedAnnual report
「During the current interim consolidated accounting period, the Group steadily laid the groundwork for building a stronger Group-wide structure by using active M&A to expand the scale of its 3 core businesses: dispensing pharmacies, healthcare and pharmaceutical wholesaling. As a result, the Group's results for the current interim consolidated accounting period were net sales of ¥22,665 million, up 29.9% year on year; operating profit of ¥828 million, up 37.4%; ordinary profit of ¥853 million, up 22.4%; and interim net profit attributable to owners of the parent of ¥709 million, up 59.7%.」
Against the previously announced targets of ¥35 billion in net sales and ¥1.5 billion in ordinary profit for the fiscal year ending February 2024, the 39th fiscal year results shown by the key indicators were net sales of ¥39,900,988 thousand and ordinary profit of ¥1,751,894 thousand, exceeding the targets numerically. The disclosure also describes scale expansion through M&A in the 3 core businesses and higher sales and profits in the current interim period. - FY2025-Q1AdvancedAnnual report
「In this way, through active M&A following the pharmaceutical wholesale business, which expanded in scale through a business integration in September 2023, the Group is further strengthening its three-pillar structure comprising the dispensing pharmacy, healthcare and pharmaceutical wholesale businesses and working to expand the scale of each business. The Group's network of locations will also expand to Tokyo, Hokkaido, 2 urban prefectures and 20 other prefectures.」
Active M&A following the integration of the pharmaceutical wholesale business strengthened the three-pillar structure, while the network of locations expanded to Tokyo, Hokkaido, 2 urban prefectures and 20 other prefectures. - FY2024-Q3AdvancedAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥28,769 million, up 13.1% year on year; operating profit of ¥1,078 million, up 52.8%; ordinary profit of ¥1,190 million, up 34.1%; and quarterly net profit attributable to owners of the parent of ¥812 million, up 36.0%.」
Net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period, indicating progress in business scale and earnings power. - FY2024-Q2AdvancedAnnual report
「Against this backdrop, the integration of the pharmaceutical wholesale business brought its sales to more than ¥10 billion, establishing a three-pillar structure whose scale is comparable to that of the dispensing pharmacy and healthcare businesses. The Group's network of locations also expanded to Hokkaido, 2 urban prefectures and 20 other prefectures, mainly in the Tokai and western Japan regions.」
The integration of the pharmaceutical wholesale business established a scale exceeding ¥10 billion in sales and a three-pillar structure alongside the dispensing pharmacy and healthcare businesses, while the network of locations expanded to Hokkaido, 2 urban prefectures and 20 other prefectures. - FY2024-Q1AdvancedAnnual report
「As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥8,721 million, up 1.8% year on year; operating profit of ¥294 million, up 23.2%; ordinary profit of ¥338 million, up 8.1%; and quarterly net profit attributable to owners of the parent of ¥211 million, up 1.9%.」
Regarding expansion of business scale and earnings power, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period in the first quarter. - FY2023Results reported ahead of the target deadlineAnnual report
「In March 2021, we formulated a medium-term management plan targeting net sales of ¥35 billion and ordinary profit of ¥1.5 billion for the fiscal year ending February 2024. We will rebuild the organization and operating structure to enable long-term, sustainable growth and advance each business.」
The company continues to target net sales of ¥35 billion and ordinary profit of ¥1.5 billion for the fiscal year ending February 2024. In the fiscal year ended February 2023, net sales were ¥33.898 billion and ordinary profit was ¥1.227 billion; sales increased, while profit declined. - FY2023-Q3Revenue Growth, Profit DeclineAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥25,427 million, up 0.9% year on year; operating profit of ¥705 million, down 30.0%; ordinary profit of ¥888 million, down 17.8%; and quarterly net profit attributable to owners of the parent of ¥597 million, down 10.9%.」
In the cumulative third quarter, net sales increased 0.9% year on year, while operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined. - FY2023-Q2Revenue Growth, Profit DeclineAnnual report
「As a result, the Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥16,978 million, up 1.0% year on year; operating profit of ¥465 million, down 27.8%; ordinary profit of ¥598 million, down 12.3%; and quarterly net profit attributable to owners of the parent of ¥374 million, down 15.7%.」
In the cumulative second quarter, net sales increased 1.0% year on year, while operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined. - FY2023-Q1Revenue Growth, Profit DeclineAnnual report
「As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥8,563 million, up 0.7% year on year; operating profit of ¥239 million, down 21.0%; ordinary profit of ¥312 million, down 1.1%; and quarterly net profit attributable to owners of the parent of ¥208 million, down 7.8%.」
In the first quarter, net sales increased 0.7% year on year, while operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined. - FY2022-Q3Higher sales, higher operating and ordinary profit, lower net profitAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥25,211 million, up 7.4% year on year; operating profit of ¥1,008 million, up 36.7%; ordinary profit of ¥1,080 million, up 29.1%; and quarterly net profit attributable to owners of the parent of ¥670 million, down 2.3%.」
While net sales, operating profit and ordinary profit exceeded the year-earlier period, quarterly net profit attributable to owners of the parent fell below it, indicating divergent trends in business scale and earnings power. - FY2022-Q2AdvancedAnnual report
「The Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥16,812 million, up 8.3% year on year; operating profit of ¥648 million, up 64.1%; ordinary profit of ¥685 million, up 70.4%; and quarterly net profit attributable to owners of the parent of ¥445 million, up 2.5%.」
In the cumulative second quarter, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period, indicating progress in business scale and earnings power. - FY2022-Q1AdvancedAnnual report
「As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥8,505 million, up 8.7% year on year; operating profit of ¥304 million, up 79.4%; ordinary profit of ¥317 million, up 93.3%; and quarterly net profit attributable to owners of the parent of ¥226 million, up 58.8%.」
Although this does not directly indicate progress against the numerical targets in the medium-term management plan, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period in the first quarter. - FY2021RaisedAnnual report
「In March 2021, we formulated a medium-term management plan targeting net sales of ¥35 billion and ordinary profit of ¥1.5 billion for the fiscal year ending February 2024. We will rebuild the organization and operating structure to enable long-term, sustainable growth and advance each business.」
In addition to the existing direction of expanding business scale and strengthening earnings power, the company newly set numerical targets of net sales of ¥35 billion and ordinary profit of ¥1.5 billion for the fiscal year ending February 2024. - FY2021-Q3Lower sales, lower operating profit and other earnings, higher net profitAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥23,484 million, down 2.3% year on year; operating profit of ¥739 million, down 18.9%; ordinary profit of ¥839 million, down 8.3%; and quarterly net profit attributable to owners of the parent of ¥687 million, up 15.6%.」
In the cumulative third quarter, net sales, operating profit and ordinary profit fell below the year-earlier period, while quarterly net profit attributable to owners of the parent increased 15.6%. - FY2021-Q2Lower sales, lower operating profit and other earnings, higher net profitAnnual report
「As a result, the Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥15,522 million, down 3.4% year on year; operating profit of ¥395 million, down 36.6%; ordinary profit of ¥402 million, down 36.4%; and quarterly net profit attributable to owners of the parent of ¥434 million, up 9.4%.」
In the cumulative second quarter, net sales, operating profit and ordinary profit fell below the year-earlier period, while quarterly net profit attributable to owners of the parent increased. - FY2021-Q1Lower sales, lower operating, ordinary and net profitAnnual report
「As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥7,823 million, down 3.4% year on year; operating profit of ¥169 million, down 49.7%; ordinary profit of ¥164 million, down 51.5%; and quarterly net profit attributable to owners of the parent of ¥142 million, down 34.6%.」
In the first quarter, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all fell below the year-earlier period. - FY2020-Q3Higher sales, higher operating and ordinary profit, lower net profitAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥24,044 million, up 2.7% year on year; operating profit of ¥911 million, up 22.6%; ordinary profit of ¥914 million, up 21.6%; and quarterly net profit attributable to owners of the parent of ¥594 million, down 1.4%.」
While net sales, operating profit and ordinary profit exceeded the year-earlier period, quarterly net profit attributable to owners of the parent fell below it, indicating divergent trends in business scale and earnings power. - FY2020-Q2AdvancedAnnual report
「As a result, the Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥16,063 million, up 2.5% year on year; operating profit of ¥623 million, up 32.5%; ordinary profit of ¥632 million, up 31.0%; and quarterly net profit attributable to owners of the parent of ¥397 million, up 3.0%.」
In the cumulative second quarter, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period, indicating progress in business scale and earnings power. - FY2020-Q1AdvancedAnnual report
「Against this business backdrop, the Group is working to secure earnings by further enhancing the functions of community-trusted family pharmacists and family pharmacies, and by further promoting the acceptance of prescriptions. In the healthcare business, the Group is developing operations to meet diversifying needs as the number of users of nursing care services increases, while working to secure a stable nursing care workforce and improve the quality of nursing care services. In addition, the Group resolved to transition to a holding company structure effective 1 September 2019, with the aim of (1) strengthening the Group management strategy function, (2) strengthening the business execution structure, and (3) strengthening the governance structure, and is preparing for the organizational reorganization. Under the philosophy of providing high-quality medical and nursing care services to more people, the Group is working to achieve further growth and enhance corporate value. As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥8,099 million, up 1.3% year on year; operating profit of ¥337 million, up 46.0%; ordinary profit of ¥338 million, up 52.8%; and quarterly net profit attributable to owners of the parent of ¥218 million, up 4.2%.」
The company continued its policy of securing earnings and pursuing organizational reorganization, and in the first quarter, net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the year-earlier period. - FY2019Higher sales, lower earningsAnnual report
「As a result, the Group's results for the current consolidated fiscal year were net sales of ¥31,222 million, up 1.0% year on year; operating profit of ¥1,043 million, down 25.8%; ordinary profit of ¥1,053 million, down 23.9%; and net profit attributable to owners of the parent of ¥711 million, down 42.5%, following the recognition of an impairment loss of ¥108 million.」
For the full fiscal year, net sales increased, while operating profit, ordinary profit and net profit attributable to owners of the parent all declined, indicating divergent trends in business scale and earnings power. - FY2019-Q3Higher sales, lower earningsAnnual report
「As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥23,404 million, up 1.1% year on year; operating profit of ¥743 million, down 36.2%; ordinary profit of ¥752 million, down 33.1%; and quarterly net profit attributable to owners of the parent of ¥602 million, down 42.7%.」
While net sales increased 1.1% year on year, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined, indicating divergent trends in business scale and earnings power. - FY2019-Q2Higher sales, lower earningsAnnual report
「As a result, the Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥15,668 million, up 1.4% year on year; operating profit of ¥470 million, down 36.0%; ordinary profit of ¥482 million, down 32.8%; and quarterly net profit attributable to owners of the parent of ¥386 million, down 49.5%.」
While net sales increased 1.4% year on year, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined, indicating divergent trends in sales scale and earnings power. - FY2019-Q1Higher sales, lower earningsAnnual report
「As a result, the Group's results for the cumulative first quarter of the current consolidated fiscal year were net sales of ¥7,996 million, up 3.1% year on year; operating profit of ¥230 million, down 39.1%; ordinary profit of ¥221 million, down 41.2%; and quarterly net profit attributable to owners of the parent of ¥209 million, down 12.7%.」
While net sales increased 3.1% year on year, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all declined, indicating divergent trends in business scale and earnings power. - FY2018AdvancedAnnual report
「Against this business backdrop, the Group anticipated growing demand for medical and nursing care services as Japan's ultra-aged society continued to develop, and worked to expand its business scale and strengthen its earnings power. As a result, the Group's results for the current consolidated fiscal year were net sales of ¥30,914 million, up 4.8% year on year; operating profit of ¥1,405 million, up 17.1%; ordinary profit of ¥1,384 million, up 20.0%; and net profit attributable to owners of the parent of ¥1,238 million, up 29.5%.」
The company continued to expand its business scale and strengthen its earnings power, with net sales, operating profit, ordinary profit and net profit attributable to owners of the parent all exceeding the year-earlier period in the current consolidated fiscal year. - FY2018-Q3AdvancedAnnual report
「In the healthcare business, we promoted the continued securing of residents for fee-based nursing homes, following the first half, and worked to expand business scale and earnings. As a result, the Group's results for the cumulative third quarter of the current consolidated fiscal year were net sales of ¥23,158 million, up 4.7% year on year; operating profit of ¥1,164 million, up 41.8%; ordinary profit of ¥1,124 million, up 44.5%; and quarterly net profit attributable to owners of the parent of ¥1,051 million, up 67.0%.」
The company advanced business scale and earnings expansion by continuing to secure residents for fee-based nursing homes following the first half, and reported cumulative third-quarter results including a 4.7% increase in net sales and a 41.8% increase in operating profit. - FY2018-Q2AdvancedAnnual report
「In the healthcare business, we promoted the continued securing of residents for fee-based nursing homes, as in the previous fiscal year, and worked to expand business scale and earnings. As a result, the Group's results for the cumulative second quarter of the current consolidated fiscal year were net sales of ¥15,456 million, up 4.7% year on year; operating profit of ¥735 million, up 38.3%; ordinary profit of ¥718 million, up 45.8%; and quarterly net profit attributable to owners of the parent of ¥765 million, up 58.1%.」
The company continued to pursue business scale and earnings expansion, with net sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeding the year-earlier period in the cumulative second quarter. - FY2018-Q1RestatedAnnual report
「Under the philosophy of providing high-quality medical and nursing care services to more people, we are pursuing further growth while working to strengthen the brands of Flower Pharmacy and Harmony House.」
The company reiterated its direction of pursuing further growth leading to business scale expansion and stronger earnings power, explicitly identifying the strengthening of both brands as the means to achieve this. - FY2017-Q3RestatedAnnual report
「While making safety the top priority, we are working to expand our business scale and strengthen our earnings power.」
The company continues to pursue growth in its business scale and earnings power while prioritizing safety. - FY2017-Q2RestatedAnnual report
「While making safety the top priority, we have worked to expand our business scale and strengthen our earnings power.」
The company continues to pursue a policy of prioritizing safety while increasing its business scale and earnings power. - FY2017-Q1First statedAnnual report
「While making safety the top priority, we have worked to expand our business scale and strengthen our earnings power.」
The company has indicated a direction of prioritizing safety while increasing its business scale and earnings power.